ICU · Seastar Medical Holding Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $495.0K | - | $183.0K | $0 | $0 | - | $68.0K | - | - | - |
| Cost of Revenue | $46.0K | - | $14.0K | $0 | $0 | - | $0 | - | - | - |
| Gross Profit | $449.0K | - | $169.0K | $311.0K | $0 | - | $68.0K | - | - | - |
| R&D | $2.34M | - | $1.85M | $1.04M | $2.43M | - | $2.34M | $2.33M | $1.70M | - |
| SG&A | $1.71M | - | $1.90M | $1.03M | $1.68M | - | $2.19M | $2.33M | $2.25M | - |
| Total Operating Expenses | $4.05M | - | $3.75M | $2.07M | $4.12M | - | $4.52M | $4.67M | $3.95M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($3.60M) | - | ($3.58M) | ($1.76M) | ($3.82M) | - | ($4.46M) | ($4.67M) | ($3.95M) | - |
| Interest Expense | $6.0K | - | $0 | $9.0K | $11.0K | - | $272.0K | $82.0K | $143.0K | - |
| Income Tax | $3.0K | - | $0 | $0 | $3.0K | - | $0 | $3.0K | $0 | - |
| Net Income | ($3.52M) | - | ($3.47M) | ($2.00M) | ($3.77M) | - | ($4.48M) | ($3.24M) | ($12.70M) | - |
| EPS - Basic | ($0.90) | - | ($1.30) | ($1.80) | ($4.40) | - | ($11.00) | ($10.30) | ($47.50) | - |
| EPS - Diluted | - | - | - | ($1.80) | ($4.40) | - | ($11.00) | ($10.30) | ($47.50) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.35M | $11.98M | $13.76M | $6.30M | $5.30M | $1.82M | $2.08M | $1.18M | $5.02M | $176.0K |
| Accounts Receivable | $179.0K | $237.0K | $221.0K | $217.0K | $110.0K | $112.0K | $68.0K | - | - | - |
| Inventory | $57.0K | $66.0K | $83.0K | $77.0K | $44.0K | $0 | $0 | - | - | - |
| Accounts Payable | $719.0K | $948.0K | $2.02M | $3.16M | $3.40M | $3.05M | $3.69M | $4.12M | $3.88M | $4.37M |
| Current Assets | $10.76M | $13.58M | $14.87M | $7.65M | $6.78M | $3.77M | $3.62M | $2.41M | $6.54M | $2.31M |
| Total Assets | $11.26M | $14.16M | $15.53M | $8.38M | $7.60M | $4.66M | $4.59M | $3.47M | $7.74M | $3.51M |
| Current Liabilities | $3.95M | $3.74M | $4.07M | $5.04M | $7.03M | $6.84M | $6.64M | $9.93M | $9.65M | $13.05M |
| Long-term Debt | - | - | - | - | - | - | $0 | $0 | $1.14M | $4.14M |
| Total Liabilities | $3.95M | $3.74M | $4.07M | $5.04M | $7.03M | $6.84M | $6.64M | $10.37M | $12.21M | $17.38M |
| Stockholders' Equity | $7.32M | $10.42M | $11.46M | $3.34M | $565.0K | ($2.18M) | ($2.05M) | ($6.90M) | ($4.47M) | ($13.87M) |
| Retained Earnings | ($155.24M) | ($151.71M) | ($148.81M) | ($145.34M) | ($143.34M) | ($139.56M) | ($135.15M) | ($130.67M) | ($127.43M) | ($114.73M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.76M) | - | - | - | ($2.65M) | - | - | - | ($3.49M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $129.0K | - | - | - | $6.13M | - | - | - | $8.33M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 90.7% | - | 92.3% | - | - | - | 100.0% | - | - | - |
| Operating margin | -727.9% | - | -1955.7% | - | - | - | -6552.9% | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | -711.3% | - | -1897.3% | - | - | - | -6585.3% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 473.5% | - | 1010.9% | - | - | - | 3435.3% | - | - | - |
| SG&A / Revenue | 345.1% | - | 1037.2% | - | - | - | 3217.6% | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -31.3% | - | -22.4% | -23.9% | -49.7% | - | -97.6% | -93.3% | -164.0% | - |
| Return on equity | -48.1% | - | -30.3% | -59.9% | -667.6% | - | 218.2% | 46.9% | 283.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.73 | 3.63 | 3.66 | 1.52 | 0.96 | 0.55 | 0.54 | 0.24 | 0.68 | 0.18 |
| Quick ratio | 2.71 | 3.61 | 3.64 | 1.50 | 0.96 | 0.55 | 0.54 | 0.24 | 0.68 | 0.18 |
| Cash ratio | 2.37 | 3.20 | 3.38 | 1.25 | 0.75 | 0.27 | 0.31 | 0.12 | 0.52 | 0.01 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | 0.00 | 0.00 | -0.25 | -0.30 |
| Debt / Assets | - | - | - | - | - | - | 0.00 | 0.00 | 0.15 | 1.18 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -600.5x | - | - | -195.1x | -347.5x | - | -16.4x | -56.9x | -27.6x | - |
| Equity multiplier | 1.54 | 1.36 | 1.35 | 2.51 | 13.45 | -2.13 | -2.23 | -0.50 | -1.73 | -0.25 |
| Liabilities / Assets | 0.35 | 0.26 | 0.26 | 0.60 | 0.93 | 1.47 | 1.45 | 2.99 | 1.58 | 4.95 |
| Efficiency | ||||||||||
| Asset turnover | 0.04 | - | 0.01 | 0.00 | 0.00 | - | 0.01 | - | - | - |
| Inventory turnover | 0.81 | - | 0.17 | 0.00 | 0.00 | - | - | - | - | - |
| Days sales outstanding | 132d | - | 441d | - | - | - | 365d | - | - | - |
| Days inventory outstanding | 452d | - | 2164d | - | - | - | - | - | - | - |
| Days payable outstanding | 5705d | - | 52612d | - | - | - | - | - | - | - |
| Cash conversion cycle | -5121d | - | -50007d | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | 14.4x | 253.2x | - | - | - | - | - |
| P / S | - | - | - | - | - | - | 2560.3x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | 169.1% | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | 148.5% | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 5.7% | - | 19.7% | 62.4% | 3.2% | - | -51.8% | -24.5% | 13.8% | - |
| Net income growth (YoY) | 6.7% | - | 22.5% | 38.1% | 70.3% | - | 39.7% | 11.8% | -141.3% | - |
| EPS growth (YoY) | - | - | - | 82.5% | 90.7% | - | -2873.0% | -8483.3% | -33828.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 1194.7% | - | - | - | - | 84.3% | 87.1% | 39.7% | 58.9% | -68.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$1.20M totalPediatric Scds$1.20M · 100.0%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing SeaStar Medical Holding Corp against the 5 most active filers in the same SIC group.